Melanoma

This study tested a new RNA cancer vaccine in 119 people with advanced melanoma. The vaccine was designed to train the immune system to attack four proteins found on melanoma cells. The main goal was to check the vaccine's safety and find the best dose, while also looking for sig…

This study tested a new type of vaccine made by fusing a patient's own immune cells with their cancer cells. The goal was to see if it was safe and could help the immune system fight advanced melanoma. Twenty adults with spreading melanoma that was getting worse took part. The va…

This study tested a personalized vaccine made from each patient's own melanoma mutations. The goal was to see if it is safe and possible to create such a vaccine. Fifteen people with advanced melanoma received the vaccine, and researchers checked for side effects and immune respo…

This early-stage trial tested a custom-made vaccine called WDVAX in 23 people with advanced melanoma. The vaccine is created from each patient's own killed tumor cells, mixed with immune-boosting proteins, and formed into a small dissolvable tablet. The goal was to see if it's sa…

This early-stage trial tests a drug called PH-762, injected directly into skin tumors, for people with squamous cell carcinoma, melanoma, or Merkel cell carcinoma. Participants receive four weekly injections into one tumor, then have it surgically removed about two weeks later. T…

Researchers are testing an experimental immunotherapy called GNR-051 in adults with advanced lung cancer, kidney cancer, or melanoma that has returned or not responded to other treatments. The Phase 1 trial aims to find the highest dose people can tolerate and to track side effec…

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This phase 2 trial tested a combination of an injected drug (LTX-315) and an intravenous immunotherapy (pembrolizumab) in 23 people with advanced melanoma that no longer responded to standard PD-1/PD-L1 inhibitors. The goal was to see if the combination could shrink tumors or slo…

This phase 2 trial tests whether adding an experimental drug called pixatimod to the immunotherapy nivolumab can shrink tumors in people with advanced melanoma, non-small cell lung cancer, or colorectal cancer that has stopped responding to prior treatment. One group with colorec…

This trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…

This trial is testing whether combining the immunotherapy drug pembrolizumab with other experimental agents can help people with advanced melanoma whose cancer has stopped responding to standard anti-PD-1 treatment. The study includes several treatment arms, each pairing pembroli…

This early-phase trial is testing whether combining two drugs—pembrolizumab (Keytruda) and ibrutinib (Imbruvica)—can safely treat advanced melanoma that cannot be removed by surgery. Pembrolizumab helps the immune system fight cancer, while ibrutinib blocks enzymes that help canc…

This phase II trial tests whether combining two immunotherapy drugs, nivolumab and relatlimab, can shrink tumors in people with metastatic melanoma who have not yet received immunotherapy. Nivolumab helps immune cells attack cancer, while relatlimab blocks a different brake on th…

This study tests whether combining an experimental drug (GSK2636771) with the immunotherapy pembrolizumab (Keytruda) can help control metastatic melanoma in patients whose tumors have lost a protein called PTEN. The trial involves up to 41 adults with advanced melanoma that hasn'…

This study tested several combinations of the immunotherapy drug pembrolizumab (Keytruda) with other experimental drugs in people with stage III melanoma that can be surgically removed. The goal was to see if these combinations are safe and more effective than current treatments …

This study tested a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 61 people with advanced melanoma or other solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drugs could s…

This study tests whether a gel containing a human growth factor (rhPDGF-BB) can help wounds heal faster after skin cancer removal on the head or neck. About 40 adults whose surgical wounds are too large to stitch closed will receive either the gel or a placebo. The goal is to see…

This early-stage trial is testing an experimental drug called AMG 355, given alone or together with the immunotherapy Keytruda, in 77 adults with advanced solid tumors (like lung, colon, stomach, or melanoma) that have not responded to standard treatments. The main goals are to c…

This phase 2 trial is testing the drug ibrutinib in 18 people with stage IV melanoma that has not responded to previous treatments. Ibrutinib works by blocking certain enzymes that help cancer cells grow. The study aims to see if the drug can shrink tumors and how long it keeps t…

This early-stage trial is testing an investigational therapy called OH2, a modified herpes simplex virus designed to infect and destroy cancer cells while also stimulating the immune system. The study will evaluate OH2 alone or in combination with the immunotherapy drug pembroliz…

This early-phase trial is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, can safely treat advanced melanoma that cannot be removed by surgery. The study includes adults with stage III or IV melanoma and focuses on the safety and tolerability of the d…

This trial is testing whether adding an experimental drug called HBI-8000 to the immunotherapy nivolumab can safely control advanced melanoma, kidney cancer, and non-small cell lung cancer. The study enrolls adults whose cancers have not responded to prior treatments. Researchers…

This phase II trial tests whether combining pembrolizumab (an immunotherapy) with lenvatinib (a targeted therapy) can control metastatic uveal melanoma, a rare eye cancer that has spread. About 51 adults are enrolled in two groups: those who have never taken Tebentafusp and those…

This trial is testing whether a modified virus called JX-594 (Pexa-Vec) can safely and effectively shrink tumors in people with advanced melanoma that cannot be surgically removed. The virus is injected directly into the tumor and is designed to infect and kill cancer cells while…

This study tested two different doses of the immunotherapy drug ipilimumab, either alone or combined with high-dose interferon, in 88 people with advanced melanoma that could not be surgically removed. The goal was to see if the combination could delay cancer growth better than i…

This study tested the drug nivolumab in 26 people with stage IIB or IIC melanoma that had been completely removed by surgery. The goal was to see if nivolumab, an immunotherapy that helps the immune system attack cancer cells, could prevent the melanoma from coming back. Particip…

This phase 3 trial compares a new drug, RPH-075, to the established immunotherapy Keytruda (both are forms of pembrolizumab) in people with advanced or spreading skin melanoma that cannot be surgically removed. The study aims to see if RPH-075 is as effective as Keytruda at shrin…

This study tests whether a new drug called RPH-075, a biosimilar of pembrolizumab (Keytruda), works as well as the original in people with skin melanoma, lung cancer, or head and neck cancer. Participants receive a single dose of either RPH-075 or Keytruda, and researchers compar…

This study tests a new drug called pegilodecakin, a lab-made version of a natural immune protein (interleukin-10), in people with advanced solid tumors such as melanoma, lung, breast, prostate, ovarian, kidney, colorectal, and pancreatic cancers. The drug is given as a daily shot…

This early-stage trial tests an experimental antibody called JS004, which targets a protein on immune cells called BTLA, to see if it can help the immune system fight advanced solid tumors like melanoma, kidney cancer, and bladder cancer. The study includes JS004 alone or combine…

This study compares a new biosimilar drug (GME751) to the standard immunotherapy Keytruda in 322 adults with stage II or III melanoma that has been surgically removed. The goal is to see if the biosimilar stays in the body and works as well as Keytruda in preventing the cancer fr…

This study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. About 161 adults took part. The main goal was to see how many patients had their tumors …

This phase 2 pilot study tests whether adding the investigational drug vidutolimod to the immunotherapy nivolumab can destroy more melanoma tumors in lymph nodes or nearby skin areas before surgery. Participants have stage IIIB/C/D melanoma that has spread but not to distant orga…

This study tested the drug larotrectinib in 215 adults with various solid cancers that have a specific change in the NTRK gene. The drug is taken orally and works by blocking the action of the altered gene. The main goal was to see how many patients had their tumors shrink or dis…

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…

This completed phase 2 trial tested whether adding alpha interferon to standard surgery helps prevent skin melanoma from returning. 278 participants with stage I-IV melanoma were assigned to one of six groups, including surgery alone, low or high dose interferon, chemotherapy, or…

This phase II trial tests whether giving two targeted drugs (dabrafenib and trametinib) before and after surgery can improve outcomes for people with stage IIIB-C melanoma that has a BRAF V600 mutation. 35 participants will take the drugs for 12 weeks before surgery, then continu…

This study tested a new approach for people with advanced melanoma that can be surgically removed. Participants received a combination of two immunotherapies: one injected directly into the tumor (Tavo) and one given through a vein (nivolumab). After 12 weeks, they had surgery to…

This phase 3 trial tested whether a yeast-derived immune stimulant (GM-CSF) and a peptide vaccine, alone or together, could prevent melanoma from returning after surgery. 815 patients with no visible cancer after complete surgical removal of advanced melanoma were randomly assign…

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This early-phase study tested an experimental drug called APX005M added to two standard immunotherapies (nivolumab and ipilimumab) in 26 people with advanced melanoma or kidney cancer who had not received prior immune therapy. The main goals were to check safety and find the best…

This early-phase study tested a personalized cancer vaccine (RO7198457) in 273 patients with advanced solid tumors like melanoma, lung, and breast cancer. The vaccine was given alone or with an immunotherapy drug (atezolizumab) to see if it was safe and how the body responded. Th…

This study tested a new approach for stage IIIB/C melanoma, the deadliest form of skin cancer. Nineteen participants received a single infusion of the immunotherapy drug nivolumab, followed by cryotherapy (freezing) of a cancerous lymph node, and then an injection of another immu…

This Phase 2 trial tested whether adding bosentan, a drug used for blood vessel conditions, to standard chemotherapy (dacarbazine) could slow tumor growth in people with stage IV melanoma. The study enrolled 80 adults with advanced melanoma and compared the combination to chemoth…

This study tested a combination of two drugs, sitravatinib (a pill) and tislelizumab (an IV infusion), in 16 people with a rare eye cancer (uveal melanoma) that had spread to the liver. The goal was to see if the combo could shrink liver tumors better than current treatments. Par…

This study looked at 216 people with advanced melanoma that had stopped responding to standard treatments. Researchers tested each person's tumor for specific genetic changes and then gave them a drug designed to target that change. The goal was to see if this personalized approa…

This study tested a drug called indoximod, taken as a pill, together with standard immune checkpoint inhibitors (ipilimumab or pembrolizumab) in 131 adults with advanced or metastatic melanoma that could not be removed by surgery. The goal was to see if the combination was safe a…

This study tested whether adding other treatments to the drug pembrolizumab can help people with advanced melanoma that hasn't been treated before. Researchers checked safety and how many people's tumors shrank or disappeared. The trial involved 335 participants and was part of a…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…

This early-phase study tested a single dose of an experimental antibody (MEDI0562) given before surgery to 13 patients with advanced head and neck cancer or melanoma. The goal was to see if the drug safely activates the immune system to fight the cancer. Researchers compared givi…

This early-stage study tested a new drug called LBL-007 combined with two other medicines (toripalimab and axitinib) in 79 people with advanced melanoma that could not be removed by surgery or had spread. The main goals were to check safety and find the best dose. Researchers als…

This early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …

This early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …

This phase 2 trial tested whether a reduced dose of chemotherapy drugs (fludarabine and cyclophosphamide) given before infusing a patient's own tumor-fighting immune cells (lifileucel) could work for advanced melanoma that has spread or can't be removed. Eleven adults with stage …

This study tested a special skin graft called X A-DERM™ mADM in 16 people who had Mohs surgery to remove skin cancers like basal cell carcinoma or squamous cell carcinoma. The graft has a micro-textured surface designed to help the wound heal faster and leave a better scar. Resea…

This study tested whether taking two targeted drugs (dabrafenib and trametinib) for 12 months after melanoma surgery could keep the cancer from returning. It included 870 adults with high-risk stage III melanoma that had a specific BRAF V600 mutation. Results showed the drug comb…

This early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients w…

This early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The …

This early study tested whether giving a single dose of nivolumab with either ipilimumab or relatlimab before surgery is safe and possible for people with melanoma that has spread to the brain. Only one person took part, so results are very limited. The goal was to see how the dr…

This phase 2 study tested a combination of oral azacitidine (a chemotherapy-like drug) and pembrolizumab (an immunotherapy) in 24 people with advanced melanoma that had spread. The goal was to see if the combo could shrink tumors or slow the disease, both in patients who had neve…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This early-phase trial tested a new personalized therapy called TBio-4101 for people with advanced melanoma that had stopped responding to standard treatments. The therapy uses a patient's own tumor-fighting immune cells, which are collected, multiplied in the lab, and then infus…

This pilot study tested whether metformin, a common diabetes drug, could help treat advanced melanoma that had spread and stopped responding to other treatments. Twenty adults with stage IIIC or IV melanoma took metformin to see if it could shrink their tumors. The goal was to fi…

This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …

This early-phase study tested whether adding a TNF-blocking drug (infliximab or certolizumab) to standard immunotherapy (nivolumab and ipilimumab) is safe for people with advanced melanoma that has spread. The main goal was to find the best dose and check for serious side effects…

This study tested whether adding denosumab (a bone-strengthening drug) to standard immunotherapy (pembrolizumab or nivolumab) could help control advanced melanoma that has spread. Researchers enrolled 25 adults with stage III or IV melanoma who had not received prior immunotherap…

This phase 3 trial tested whether ABP 206, a biosimilar to the cancer drug nivolumab (Opdivo), works similarly in people with advanced melanoma that has been surgically removed. 256 participants received either ABP 206 or Opdivo every 4 weeks for a year. The goal was to see if th…

This phase 2 trial tested a personalized cell therapy called lifileucel for people with advanced melanoma that had spread and stopped responding to standard treatments. Researchers took immune cells from each patient's tumor, multiplied them in a lab, and infused them back after …

This early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…

This study tested a new drug called IMCgp100 in 378 adults with a specific genetic type (HLA-A*0201) of advanced uveal melanoma, a rare eye cancer. Participants received either IMCgp100 or one of three standard treatments (dacarbazine, ipilimumab, or pembrolizumab). The main goal…

This early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…

This early-phase study tested whether combining a topical cream (imiquimod) with an immunotherapy drug (pembrolizumab) is safe and effective for people with advanced melanoma that has spread. Seven participants with stage IIIB to IV melanoma were enrolled. The goal was to see if …

This early study tested the safety of an experimental drug called MK-4700, given alone or with the approved immunotherapy Keytruda, in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body h…

This early study tested combining the immunotherapy drug pembrolizumab with precise radiation (stereotactic radiosurgery) in 25 people with melanoma or lung cancer that had spread to the brain. The main goal was to check for serious side effects. Researchers also tracked how long…

This early-stage trial tested a personalized vaccine made from a patient's own immune cells and tumor material for people with metastatic uveal melanoma, a rare eye cancer that has spread. The vaccine was added to standard treatments like immunotherapy or chemotherapy. The main g…

This study tested an experimental drug called ENV-101 (taladegib) in 20 adults with advanced solid tumors that have a specific genetic mutation (PTCH1 loss-of-function). The drug works by blocking a growth pathway in cancer cells. Researchers measured how many patients' tumors sh…

This phase 3 trial tested a combination of two targeted drugs, LGX818 and MEK162, against standard treatments in 921 people with advanced melanoma that has a BRAF V600 mutation. The study compared the combo to vemurafenib alone or LGX818 alone to see which worked better at delayi…

This early-phase trial tested a combination of two oral drugs, trametinib and ceritinib, in 27 people with advanced melanoma that had stopped responding to prior treatments. The main goals were to find a safe dose and see if the combination could shrink tumors. The study is compl…

This study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…

This phase II trial tested a powerful combination for people with advanced melanoma that has spread. The approach uses a targeted drug (vemurafenib), immune cells grown from the patient's own tumor (TIL), and high-dose IL-2 to boost the immune system. The study enrolled 17 partic…

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that hasn't been treated yet. About 674 adults with stage III or IV melanoma took part. The goal was to see if the combination helps people live lo…

This study tested a new way to do stem cell transplants in 23 children with cancers that came back or didn't respond to treatment. The method removes certain immune cells from the donor's stem cells to help the child's body recover faster and fight infections better. The goal was…

This study tested two different doses of an experimental drug called RO7247669 in 93 people with advanced melanoma that had not been treated before. The goal was to see how well the drug controls the cancer and to find the best dose with the fewest side effects. Participants rece…

This early-phase study tested whether genetically modified T-cells (MAGE-A10ᶜ⁷⁹⁶T) are safe for people with advanced urothelial cancer, melanoma, or head and neck cancer. Ten participants received their own engineered immune cells after chemotherapy. The main goal was to check fo…

This study tested whether adding a personalized cancer vaccine (RO7198457) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that hasn't been treated before. The trial involved 131 participants and measured how long th…

This early-phase study tested a new drug called IN10018, alone or with other medicines, in 51 adults with advanced melanoma that had spread. The main goal was to check safety and how the body handles the drug. The study included people with two hard-to-treat types of melanoma: uv…

This early-stage study tested an experimental drug called PLX3397 in 6 people with advanced melanoma that has a specific KIT gene mutation and cannot be removed by surgery. The goal was to check the drug's safety and see if it could shrink tumors. While some patients had their tu…

This study tested a combination of two immunotherapy drugs, low-dose ipilimumab and pembrolizumab, in 24 people with advanced melanoma that had spread to the brain. The goal was to see if the treatment could shrink or control brain tumors and improve survival. Participants receiv…

This phase 2 trial tested a combination of an experimental cancer vaccine (BNT111) and an immunotherapy drug (cemiplimab) in 184 adults with advanced melanoma that no longer responded to standard immunotherapy. Participants were randomly assigned to receive the combination or eit…

This early-phase study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. The trial is no…

This trial tested a two-step treatment for people with advanced solid tumors that no longer respond to standard therapies. First, a laser heats and destroys part of the tumor. Then, a drug called IP-001 is injected directly into the treated area to help the immune system recogniz…

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma who haven't had prior treatment. It involved 131 Chinese participants with stage III or IV melanoma that could not be removed by surgery. The goal …

This early-phase trial tested a new drug called NB003 in 258 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. The study is now complete, an…

This trial tested a new treatment called GC101 TIL for people with advanced melanoma that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to the patient. The study enrolled 18 partici…

This study tested a new way to treat metastatic melanoma by using a patient's own immune cells. Doctors removed a tumor, grew special immune cells (TILs) from it in a lab, then gave them back to the patient along with high-dose IL-2. Before the cell infusion, patients received st…

This study tested an experimental treatment for metastatic melanoma using a patient's own immune cells (tumor-infiltrating lymphocytes) grown in a lab and given back along with high-dose IL-2. Before the cell infusion, all patients received chemotherapy to suppress their immune s…

This pilot study tested a new combination treatment for people with advanced melanoma that has spread. It combined a patient's own immune cells grown in a lab (called TILs) with an immunotherapy drug called ipilimumab. The main goals were to see if the treatment was safe and poss…

This phase II trial tested whether adding bevacizumab to the immunotherapy drug ipilimumab helps people with advanced melanoma that cannot be removed by surgery. The study enrolled 169 participants and measured overall survival and tumor progression. The goal was to see if the co…

This early-phase trial tested a personalized immunotherapy for people with advanced solid tumors. Doctors removed a sample of each patient's tumor, grew the immune cells (TILs) in a lab, and then infused them back along with another drug. The goal was to see if this approach is s…

This early-phase trial tested a new drug called CyPep-1, injected directly into tumors, combined with the immunotherapy pembrolizumab (Keytruda) in 6 people with advanced head and neck cancer, melanoma, or triple-negative breast cancer. The main goal was to check safety and side …

This phase 2 trial tested a combination of two drugs—BO-112, injected directly into tumors, and pembrolizumab, given through a vein—in 42 adults with advanced melanoma that had stopped responding to standard immunotherapy. The goal was to see if the combo could shrink tumors and …

This early-phase trial tested a new way to treat advanced cancers that have spread. It combined a special type of radiation with two immunotherapy drugs (MEDI4736 and tremelimumab) to see if the combination is safe and tolerable. The study included 53 adults with advanced melanom…

This early-stage trial tested a new drug called CFT1946, alone or with other drugs, in 89 adults with solid tumors that have a BRAF V600 mutation, including melanoma, lung, colon, and thyroid cancers. The main goals were to check safety and find the best dose. The study is comple…

This study tested a treatment for uveal melanoma that has spread to the liver. Tiny radioactive beads were injected into the liver's blood vessels to deliver radiation directly to tumors. The goal was to shrink or control the liver tumors. 48 patients took part, and the study loo…

This study tested giving the cancer drug nivolumab as a shot under the skin (instead of through an IV) to people with advanced cancers like lung, kidney, melanoma, liver, and colorectal cancer. The main goal was to see how the drug moves in the body and to check for side effects.…

This study tested an experimental drug called BDB001 in people with advanced solid tumors (like skin, lung, or kidney cancer) that had stopped responding to standard immunotherapy. The goal was to see if BDB001 could shrink tumors or slow their growth. Only one person took part, …

This early-phase trial tested a new drug called INCA32459 in 46 people with advanced cancers that had spread. The main goals were to check safety, find the right dose, and see how the body handles the drug. It is too early to know if the drug works, but the results will guide fut…

This study tested a smartphone app to help young adult cancer survivors (ages 18-39) lose weight. The app tracked diet and activity as part of a behavioral weight loss program. The goal was to see if this approach was practical and well-liked by participants. The study involved 6…

This study tested a combination of an oral bacterial product (VE800) and the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The goal was to see if the bacteria could help the immune system fight tumors …

This early-phase trial tested a new approach for people with advanced melanoma that cannot be removed by surgery. The treatment combines a gene therapy injected directly into tumors with an oral drug that activates the therapy. The goal was to see if the combination is safe and t…

This completed phase 1/2 trial tested the safety and effectiveness of pembrolizumab (Keytruda) alone or combined with other drugs (quavonlimab or lenvatinib) in 56 people with melanoma that had spread to the brain. Participants had not received steroids recently and were neurolog…

This study tested a new drug called E7386 combined with the immunotherapy pembrolizumab (Keytruda) in 89 people with advanced melanoma, colorectal cancer, or liver cancer. The goal was to see if the combination is safe and can shrink tumors. Some participants with liver cancer al…

This phase 2 trial tested a drug called Taxoprexin (DHA-paclitaxel) in 22 people with metastatic uveal melanoma, a rare eye cancer that has spread. The drug was given weekly for 5 weeks in a 6-week cycle. The main goal was to see if tumors shrank or disappeared, and to check safe…

This early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This study tested a weekly injection of a new chemotherapy drug called Taxoprexin in 30 people with advanced melanoma that had spread to other parts of the body. The goal was to see if the drug could shrink tumors and how long that effect might last. Researchers also monitored si…

This early-phase trial tested whether it is safe and feasible to give patients their own immune cells (called tumor infiltrating lymphocytes, or TIL) directly into the liver artery. Eight adults with melanoma that had spread to the liver received the TIL infusion along with chemo…

This Phase 2 trial tested a modified polio virus called lerapolturev, alone or combined with an immunotherapy drug, in 27 adults with advanced melanoma that had stopped responding to standard PD-1 therapy. The virus was injected directly into tumors to trigger an immune attack. R…

When a general practitioner spots a skin lesion that might be melanoma, the patient is referred to a dermatologist, but some never go and others wait too long. This trial tests whether the GP calling the dermatologist directly and emailing a smartphone photo of the lesion shorten…

Researchers are studying whether a blood test can detect the BRAF V600E mutation in people with melanoma. The trial enrolls patients with advanced melanoma and those with earlier-stage disease after surgery. By comparing blood samples to standard tumor tissue tests, they aim to s…

This study looked at whether a special PET scan (18FDG dual-point) can tell the difference between real tumor growth and harmless inflammation caused by immunotherapy. Researchers studied 100 people with advanced lung cancer or melanoma who were being treated with drugs like nivo…

This trial tests whether indocyanine green, a dye injected before surgery, can find sentinel lymph nodes as reliably as the standard technetium-99 radioactive tracer. About 744 adults with various cancers will receive both agents, and surgeons will compare detection rates using a…

This trial tests whether a new hybrid tracer, ICG-99mTc-nanoscan, can replace the standard tracer for sentinel node biopsy in people with penile cancer, melanoma, or oral cancer. The hybrid tracer combines a fluorescent dye with a radioactive marker, potentially allowing surgeons…

This study tests a special SPECT imaging agent that seeks out a protein called LRRC15, found on many aggressive cancers like pancreatic, breast, lung, and brain tumors. The goal is to see if this scan can help doctors diagnose and stage these cancers more accurately. Healthy volu…

This study tested whether a simple breath test can predict if cancer patients will respond to immunotherapy drugs. Researchers used an electronic nose device to analyze breath samples from 190 patients with lung, melanoma, kidney, bladder, or head and neck cancers. The goal is to…

This study tested whether a special PET scan (called 18F-DOPA PET-CT) can find brain metastases as well as or better than standard MRI in people with lung cancer, breast cancer, or melanoma. 32 adults with untreated brain metastases took part. The goal was to see if this PET meth…

This study tested whether an artificial intelligence (AI) system can help detect melanoma, a dangerous form of skin cancer. Researchers took photos of suspicious skin spots from 105 adults using a smartphone camera and let the AI analyze them. They compared the AI's results to di…

This completed study tested whether an AI device could help 16 doctors (10 general practitioners and 6 dermatologists) more accurately diagnose 13 different skin conditions, including melanoma, psoriasis, and acne. The doctors reviewed 29 medical images, first giving a diagnosis …

This study tested whether an artificial intelligence (AI) tool could help primary care doctors diagnose skin conditions more accurately. Nine doctors reviewed 30 images of various skin problems, first giving their own diagnosis and then a final diagnosis after seeing the AI's sug…

This study tests a program called FLARE that teaches families how to protect children from the sun. It includes children ages 8 to 17 who have a parent who survived melanoma and who have had at least one sunburn in the past year. Families are randomly assigned to either the FLARE…

This completed study tested a school-based educational program to improve sun protection among 38 rural Utah high school students. The program included a 90-minute session with skin cancer education, a risk self-assessment, and creating a personal sun protection plan. Surveys mea…

This study looked at whether giving people personalized information about their genetic risk for melanoma could encourage them to protect themselves from the sun. Over 2,000 adults received either standard sun safety tips or tailored advice based on their DNA. Researchers then tr…

This trial tests whether a structured patient education program can lower the risk of severe immune-related side effects in people receiving immunotherapy for certain cancers, including melanoma, lung, kidney, and head and neck cancers. Participants either attend five educational…

This study tests whether a conversation game called 'Hello' can help people with cancer and their loved ones discuss advance care planning—decisions about future medical care. Participants will play either the Hello game or a similar conversation game, complete questionnaires, an…

This early-phase trial is testing whether an experimental form of radiation therapy, called FLASH, can safely treat skin lesions from metastatic melanoma. FLASH delivers radiation in a fraction of a second, which may spare healthy tissue while still targeting tumors. The study wi…

This trial tests whether a wearable sensor called the Alio Smart Patch can help catch early signs of febrile neutropenia, a serious infection risk from chemotherapy. Thirty adults with certain cancers will wear the patch and a glucose monitor at home, with a remote care team watc…

This study tested Emotional Freedom Techniques (EFT), a therapy that combines talking with gentle tapping on acupressure points, in 56 people who had been treated for melanoma and were in remission. The goal was to see if EFT could reduce fear of the cancer coming back and improv…

This study tested whether breathing in lavender essential oil for 15 minutes before skin cancer surgery could reduce anxiety. Sixty-six adults with early-stage melanoma or other skin cancers took part. Researchers measured anxiety using questionnaires and vital signs like heart r…

This study measured anxiety in 100 patients undergoing Mohs surgery for skin cancer. Researchers compared anxiety levels between first-time and returning patients, and also tested whether reading a short story about a typical patient's experience helped reduce anxiety. The goal i…

This study tested a therapy called Managing Cancer and Living Meaningfully (CALM) to see if it helps people with brain cancer feel less distressed. 60 adults with brain tumors or brain metastases who had high depression or death anxiety took part. The study measured how many peop…

Researchers are examining skin cancer among people whose jobs involve long hours in the sun. The study uses national administrative and medical records to describe who develops these cancers, including age, sex, region, cancer type, and disability outcomes. The goal is to underst…

Researchers want to learn which molecules on cancer cells the immune system attacks when checkpoint inhibitor drugs work well. They collect tumor and blood samples from adults with solid tumors who respond to these drugs, either during treatment or after surgery. The team then se…

This trial tests whether a 15-minute educational video and a list of suggested questions can improve understanding of immunotherapy among patients with advanced cancer and their caregivers. Participants are randomly assigned to receive the educational materials or usual care, and…

This trial tests whether an online training course, called MelaMEd, can improve primary care doctors' ability to detect and manage melanoma, the most serious form of skin cancer. Participants—general practitioners, trainees, and pediatricians—answer questions and review skin lesi…

This study tracked immune cell changes in 5 people with advanced melanoma who were taking nivolumab with or without ipilimumab. Researchers took blood and skin samples at several time points to compare immune responses between those who responded to treatment and those who did no…

This study looks at how tumors evolve when treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers will take blood samples and tumor biopsies from 14 people with advanced head and neck cancer or melanoma to track genetic changes. The goal is to understand …

This study enrolled 500 skin cancer patients in China and analyzed over 1.2 million of their social media posts using artificial intelligence. The goal was to see if AI could detect signs of psychological distress and suicidal thoughts. Researchers hope this approach could lead t…

This completed study looked at 40,000 people with metastatic cancer who received the drug nivolumab. Researchers compared the old way of dosing (based on body weight) with a newer, simpler fixed dose. They used national health data to see if the fixed dose was just as good and mo…

This study brought together four expert skin pathologists to see how well they agree when diagnosing moles that might be melanoma. The goal was to create a reliable standard for future research. The experts reviewed images and discussed tricky cases to reach a consensus.

This study examines the patient profiles and treatment patterns of adults with melanoma in Japan who were prescribed either dabrafenib with trametinib or encorafenib with binimetinib. Researchers are looking at data from 2012 to 2021 to understand patient characteristics and how …

This study explored whether lab-grown skin models containing a patient's own melanoma cells could predict which drug combinations would work best. Researchers took a small sample of a skin metastasis and used it to create 3D cultures and artificial skin. The goal was to test diff…

This study watched 152 melanoma patients who had their tumors surgically removed and then started nivolumab as part of their normal care. Researchers tracked how long patients stayed cancer-free, whether the cancer spread, and overall survival. The goal was to see how well the dr…

This completed study examined 127 melanoma patients to understand how the IL4I1 enzyme influences disease progression and resistance to treatments like immunotherapy and targeted therapy. Researchers analyzed blood and tumor tissue samples before and after treatment. The goal was…

This study tested whether implanting tiny gold markers near spinal tumors helps deliver radiation more accurately. Researchers also checked if giving slightly more radiation to the nearby esophagus is safe, which might improve tumor control. The study involved 41 adults with vari…

This study tested whether a family history app can help doctors collect and use information about patients' family health risks. Over 600 adults aged 30-69 took part. The goal was to see if the app leads to better screening and genetic referrals for conditions like cancer, heart …

This completed study involved 116 people with advanced melanoma. Researchers aimed to create a platform that goes beyond standard genetic testing to deeply profile tumors using advanced molecular technologies. The goal was to discover new biomarkers and help doctors make better t…

This study involved 60 people with advanced melanoma who were already scheduled to receive immunotherapy drugs. Researchers collected blood samples and, when possible, tumor samples before and during treatment to look for biological markers that might predict whether the treatmen…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This study examined blood and tumor samples from 25 people with advanced melanoma who were starting standard pembrolizumab treatment. Researchers looked at T cells—key immune cells—to find patterns that might predict whether the therapy works. The goal is to better understand why…

This study looked at 22 people with advanced (Stage IV) melanoma to see if DNA floating in their blood could show genetic changes in their cancer before and after chemotherapy. Researchers compared the DNA found in blood samples with the original tumor's genetics. The goal was to…

This study looked at whether people with advanced cancers (melanoma, kidney, or lung cancer) receiving their first immunotherapy treatment could successfully collect small blood samples at home using a finger-prick method. The goal was to see if this approach is practical and rel…

This study looked at 14 adults with melanoma who were taking a combination of BRAF and MEK inhibitor drugs. The goal was to understand how these drugs can affect the retina, the light-sensitive part of the eye. Researchers used eye exams and special imaging to track changes over …

This study looked at immune cells (T cells, NK cells, and macrophages) inside melanoma tumors from 217 patients. The goal was to understand how these cells affect the body's ability to fight the cancer and how chemotherapy might change them. It was an observational study, not a t…

This completed study looked at 132 people with advanced melanoma to see if levels of a protein called interferon-gamma (IFN-γ) in their tumors or blood could predict how well they would respond to first-line immunotherapy drugs like pembrolizumab, nivolumab, or a combination. The…

This study examined 30 people with melanoma who were taking BRAF/MEK inhibitor drugs to see how often these drugs cause retinal changes (MEKAR) and what those changes look like. Participants had regular eye exams before, during, and after treatment. The goal was to better underst…

This study tested whether an artificial intelligence (AI) tool could help primary care doctors more accurately diagnose skin conditions and decide which patients need to see a skin specialist. 131 adults with various skin issues, including possible skin cancer, took part. Doctors…

This study followed 187 melanoma patients treated with IMLYGIC, a modified herpes virus that attacks cancer cells. Researchers tracked whether the virus spread to patients' close contacts or healthcare providers, and monitored long-term safety for up to 5 years. The goal was to u…

This completed study collected blood and tumor tissue from 64 patients with advanced cancers (like melanoma, breast, lung, and kidney cancer) to study genetic changes and treatment resistance. The samples are stored for future research, including genomic analysis. No new treatmen…

This small pilot study tested whether special PET scans (FLT PET/CT) could detect early signs that immunotherapy is working in people with advanced melanoma. Five participants received standard immunotherapy drugs (pembrolizumab or nivolumab) and had scans, blood tests, and tumor…

This completed trial tested an interactive survivorship program for adolescent and young adult cancer survivors. The program included a mobile app, telehealth support, and printed materials to help survivors access healthcare resources, improve self-management skills, and reduce …

This study looked at whether a simple blood sample can detect genetic mutations in patients with advanced melanoma. Currently, doctors need to take a piece of the tumor (biopsy) to check for key gene changes that guide treatment. The goal was to see if circulating tumor DNA in th…

This completed study tested whether an interactive website could help 485 melanoma survivors do better at protecting their skin from the sun and checking their skin for new or returning cancers. Participants used the website and reported how often they used sunscreen, wore protec…

This study followed about 400 adults with advanced BRAF-mutant melanoma who were taking targeted therapy (BRAF/MEK inhibitors) and using a smartphone app called TavieSkin. The goal was to describe patient characteristics, how they used the app, their quality of life, and treatmen…

This completed study from Memorial Sloan Kettering Cancer Center looked at how people with a close family member who had melanoma make decisions about sun protection. Researchers interviewed 94 participants and used an electronic diary to track daily behaviors like sunscreen use …

This study looked at 98 adults with cancers like melanoma and lung cancer who were starting immunotherapy. Researchers measured inflammatory markers in their blood to understand how the body reacts to these drugs. The goal was to find ways to better manage side effects from treat…

This study looked at whether giving a written sheet to melanoma patients, to pass on to their close relatives, helps those relatives get a skin exam from a doctor. 420 patients and their family members took part. The goal was to see if the written reminder works better than just …

This study tested a new blood test (liquid biopsy) to find cancer markers in 135 people with head and neck, lung, or skin cancer. The goal was to see if the blood test works as well as a standard tissue biopsy. The study did not provide treatment but aimed to improve how doctors …

This study looked back at the medical records of 232 adults with advanced melanoma to find out which factors—like patient traits, tumor features, and treatments—are linked to better outcomes. Researchers reviewed data from people treated between 2022 and 2024 at hospitals in Türk…

This study looked at how well the combination of dabrafenib and trametinib works in real-life settings for people with high-risk stage III melanoma that has been completely removed by surgery. It included 39 adults in Turkey whose melanoma had a specific genetic mutation (V600E).…

This study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…

This study looked at whether a special training program could help primary care doctors better spot and treat early-stage skin cancer, especially melanoma. Fifty-four doctors from two clinics took part. The training aimed to improve their knowledge and skills in identifying suspi…

This completed study examined whether healthy skin near a melanoma tumor contains hidden cancer stem cells that might predict the disease's return. Researchers analyzed tissue from 226 people with early-stage melanoma to see if these cells are linked to 5-year survival. The goal …

This study compared two blood test methods, EPISPOT and CellSearch, to see how well they detect circulating melanoma cells in people with advanced melanoma. Researchers took blood samples from 73 participants, including patients with stage 4 melanoma and hospitalized controls wit…

This completed study looked at 100 adults with stage III melanoma that could be removed by surgery. Researchers compared two immunotherapy drug combinations given before surgery: nivolumab plus relatlimab versus nivolumab plus ipilimumab. The goal was to understand patient charac…

This study looked at 32 people with advanced melanoma who were treated with the immunotherapy drug Nivolumab. Researchers took blood samples before and during treatment to track changes in immune cells. The goal was to find differences between patients whose tumors shrank or stay…

This study tested a method to identify immune cells (T cells) that recognize unique mutations in tumors. Researchers took blood and lymph node samples from 25 patients with breast cancer or melanoma. The goal was to see if they could find and measure these cancer-specific immune …